Merck remains confident ahead of Keytruda’s loss of exclusivity, projecting growth through new drug developments and expanded indications, signaling resilience amid increasing competition.
Browsing: Merck
Merck pledges nearly $2 billion to acquire an oral lipid-lowering drug from a Chinese biotech, aiming to expand its cardiovascular portfolio and address global cholesterol management needs.